No Prescription |
 |
 | ||
|
Exermet P 515 Actosplus Met |
|
| ||
No Prescription » Prescription Drugs 7 » Exermet P 515 Actosplus Met Treating type 2 diabetes. It is used along with diet and exercise. It may be used alone or with other antidiabetic medicines.Metformin/Pioglitazone is a biguanide and thiazolidinedione antidiabetic combination. It works by decreasing the amount of sugar the liver produces and the intestines absorb. It also helps to make your body more sensitive to the insulin that you naturally produce.Adjunct to diet and exercise to improve glycemic control in patients with type 2 diabetes who are already treated with pioglitazone plus metformin or whose diabetes is not adequately controlled with metformin alone or for those patients who initially responded to pioglitazone alone and require additional glycemic control. Buy Exermet P 515 Actosplus Met and other Prescription Drugs 7 products online at Medstore. Buy Online at Medstore - Click Here!
About Exermet P 515 Actosplus Met: Product Type: Prescription Drugs 7 Exermet P (515) ( Actosplus Met Generic Pioglitazone & Metformin ) Exermet P (515 Actosplus Met Generic Pioglitazone & Metformin) 515 Actosplus Met Generic Pioglitazone & Metformin 15mg/500mg 180 Tablets 90 Tabs 515 Actosplus Met Generic Pioglitazone & Metformin Exermet P
View more Prescription Drugs 7 No Prescription: NEW YORK, Oct. 5, 2011 /PRNewswire via COMTEX/ -- Reportlinker.com announces that a new market research report is available in its catalogue: European Pharmaceutical Market: Strategic Assessments of Leading Suppliers http://www.reportlinker.com/p0651431/European-Pharmaceutical-Market-Strategic-Assessments-of-Leading-Suppliers.html #utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication This report provides industry executives with strategically significant competitor information and analysis of the leading players in the European pharmaceutical market. The report provides a worldwide strategic overview of the pharmaceutical market, including: Sales forecast for major product segments: ethical, OTC, generics. Sales forecast for major drug categories: cardiovascular, gastrointestinal, antibiotic, CNS, respiratory, musculoskeletal, hormonal/genitourinary, dermatological, oncological, ophthalmic, and others. In addition, the report reviews major regulatory, technological, economic, demographic, and social trends with potentially significant impact on the market during the next five years, including discussion of such key issues as pricing, industry consolidation, market globalization, growing R&D cost, generics, as well as advances in genomics, proteomics, drug screening, tissue engineering, bioinformatics, and other technologies. The companies analyzed in this report include Abbott, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, Pfizer, Roche, Sanofi-Aventis and Wyeth.
| ||
